




# The Gap in Childhood Immunization in the Time of COVID-19

Melinda Wharton, MD, MPH  
Immunization Services Division

Current Issues in Immunization Webinar  
14 July 2021


# The number of visits to ambulatory practices declined nearly 60 percent in mid-March and has remained low through mid-April.



Note: Data are presented as percentage change in number of visits in a given week from the baseline week (March 1–7). Data for week of April 12 are through April 16.

Source: Ateev Mehrotra et al., "What Impact Has COVID-19 Had on Outpatient Visits?," *To the Point* (blog), Commonwealth Fund, Apr. 23, 2020. <https://doi.org/10.26099/ds9e-jm36>

# Weekly changes in Vaccines for Children program provider orders for pediatric vaccines – United States, January 6-April 19, 2020




\* VFC data represent the difference in cumulative doses of VFC-funded noninfluenza and measles-containing vaccines ordered by health care providers at weekly intervals between Jan 7–Apr 21, 2019, and Jan 6–Apr 19, 2020.

Santoli JM et al, MMWR (May 8, 2020)

# VFC provider orders have rebounded...

Comparison of FY19 Weekly Provider Orders to FY20 and FY21 - All Non-Flu Vaccines



Notable Dates:

- 1 1/20/2020: First US case reported (Washington state)
- 2 3/13/2020: US national emergency declared

# ...but there still is a substantial deficit for 2020-2021

Comparison of FY19 Weekly Provider Orders to FY20 and FY21 - All Non-Flu Vaccines and Measles Containing Vaccines



**Notable Dates:**

- 1 1/20/2020: First US case reported (Washington state)
- 2 3/13/2020: US national emergency declared

As of July 11, overall VFC provider orders (other than flu) are down by


**12.5M doses** with MMR/MMRV down by **1.6M doses**

Other data show **a slower recovery in the public sector compared with the private sector**

# The COVID-19 gap is larger for some pediatric vaccines than others

- Many vaccines primarily given to younger age children have smaller gaps than those given to older kids.
  - Rotavirus vaccine – down 5.7%
  - PCV13 – down 8.1%
  - DTaP-containing vaccines – down 8.7%
  
  - Tdap – down **17.2%**
  - HPV – down **18.1%**
  - Meningococcal conjugate vaccine – down **13.9%**
  
- ***Measles-containing vaccines are down by 18.5%***


# Influenza vaccination coverage among children is lower than last season, and disparities by race and ethnicity have widened



Through week ending January 2, 2021

# % OF MISSED WELLNESS VISITS

## Middle-upper income households



Share

Health (still) interrupted - WEEK 17



Center for Translational Neuroscience (2020, October 13). *Medium*. <https://medium.com/rapid-ec-project/health-still-interrupted-pandemic-continues-to-disrupt-young-childrens-healthcare-visits-e252126b76b8>



# ‘They got back to us’: How one school built trust and got reluctant parents to return



Third-grader Za'Quan Daniels, 9, celebrates a correct answer with social worker Alyce Hairston at Patterson Elementary School in Southwest Washington on Friday. (Evelyn Hockstein for The Washington Post)

“Many are unable to return because they lack the immunizations required to enter the buildings. Youth vaccinations have plummeted during the pandemic, and nurses at Patterson are working with these families to schedule appointments at a nearby clinic.”

# The need for catch-up vaccination is urgent as we plan for safe return to in-person school

- Many school-aged children missed recommended vaccines over the last year due to disruptions associated with COVID-19
  - Especially concerning are gaps for measles vaccine and vaccines routinely recommended at 11-12 years of age
- Schools may not have focused on compliance with school vaccination requirements during the 2020-2021 school year
- We need to get children caught up on vaccine doses they missed so that they can safely return to in-person learning
- Now that COVID-19 vaccine is available for younger adolescents, we still need to assure that catch-up efforts continue for routine vaccines

# Call to Action: Kids Need to Get Caught Up on Recommended Vaccines for Safe Return to School

- Healthcare systems and healthcare providers should:
  - Identify families whose children have missed doses and contact them to schedule appointments
  - Prompt clinicians when these children are seen to deliver vaccines that are due or overdue
  - Let families know what precautions are in place for safe delivery of in-person services
- Healthcare provider organizations should:
  - Encourage members to identify and follow up with families whose children have missed doses to get appointments scheduled

# Call to Action: Kids Need to Get Caught Up on Recommended Vaccines for Safe Return to School

- Schools and state and local governments agencies should:
  - Send reminders to families about school immunization requirements
  - Follow-up with families of children who are not in compliance with requirements to encourage compliance
  - Use the state's immunization information system's reminder-recall capacity to notify families whose children have fallen behind on vaccines
- We all should:
  - Communicate directly to families the importance of well-child visits and getting caught up on any recommended vaccines that were missed


# Catch-up Vaccination

# Catch-up Priorities – COVID-19 Pandemic


- Children- newborns, infants and children up to 24 months of age, young children, and extending through adolescence
- Pregnant women – Tdap and influenza vaccines should be administered at the next prenatal appointment
- Adults – follow the Standards for Adult Immunization

# Catch-up Vaccination Strategies


Reminder/recall systems



Forecasting through EHR or IIS\*




Standing orders



\*Electronic health record (EHR) or immunization information system (IIS)  
U.S. Community Preventive Services Task Force. Guide to Community Preventive Services. Vaccination Programs. <https://www.thecommunityguide.org>; Photo credit: Noun project

# Vaccination Documentation

Because patients may be receiving vaccines outside their medical home, it is critical all vaccinations are documented in an Immunization information system (IIS) or electronic health record (EHR) for accurate and timely information on patient vaccination status.





# Persons with Suspected or Confirmed COVID-19

- Routine vaccination should be deferred for persons with suspected or confirmed COVID-19, regardless of symptoms.



# Implement Enhanced Infection Control Measures


- Screen patients for COVID-19 symptoms before and during the visit.
- Maintain physical distancing (at least 6 feet apart, where possible).
- Limit and monitor facility points of entry and install barriers to limit physical contact with patients at triage.
- Practice respiratory hygiene (facemasks for staff and cloth face coverings for patients over 2 years of age, if tolerated) and cough etiquette.
- Practice hand hygiene (including at least 60% alcohol hand sanitizer for patients).
- Enhance surface decontamination.

Refer to guidance to prevent the spread of COVID-19 in

<https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html>


# Use Personal Protection Equipment

## Face Mask




- **Recommended:** All healthcare providers (N95 masks not recommended)

## Eye Protection



- **Recommended:** Areas of moderate/substantial community transmission
- **Optional:** Areas of minimal/no community transmission


## Gloves



- **Recommended:** Intranasal or oral vaccines
- **Optional:** Intramuscular or subcutaneous vaccines

# Ensure Physical Distancing during Vaccination Visits

## Separate Sick from Well Patients




- Schedule well and sick visits at different times of the day.
- Place sick patients in different areas of the facility or different locations.

## Ensure Physical Distancing Measures



- At least 6 feet during all aspects of visit: check-in, checkout, screening procedures, postvaccination monitoring
- Use strategies such as physical barriers, signs, ropes, floor markings.


## Reduce Crowding in Waiting Room



- Ask patients to wait outside (e.g., in their vehicles) until called in.


# Special Adolescent Concern

History of immediate allergic reaction (any severity) to a vaccine or injectable therapy  
Contraindication to a different type of COVID-19 vaccine  
History of anaphylaxis (due to any cause)



30 minutes

All other persons



15 minutes

# Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger

UNITED STATES  
2021

## Vaccines in the Child and Adolescent Immunization Schedule\*

Vaccines	Abbreviations	Trade names
Diphtheria, tetanus, and acellular pertussis vaccine	DTaP	Daptacel® Infanrix®
Diphtheria, tetanus vaccine	DT	No trade name
<i>Haemophilus influenzae</i> type b vaccine	Hib (PRP-T) Hib (PRP-OMP)	ActHIB® Hiberix® PedvaxHIB®
Hepatitis A vaccine	HepA	Havrix® Vaqta®
Hepatitis B vaccine	HepB	Engerix-B® Recombivax HB®
Human papillomavirus vaccine	HPV	Gardasil 9®
Influenza vaccine (inactivated)	IIV	Multiple
Influenza vaccine (live, attenuated)	LAIV4	FluMist® Quadrivalent
Measles, mumps, and rubella vaccine	MMR	M-M-R II®
Meningococcal serogroups A, C, W, Y vaccine	MenACWY-D MenACWY-CRM MenACWY-TT	Menactra® Menveo® MenQuadfi®
Meningococcal serogroup B vaccine	MenB-4C MenB-FHbp	Bexsero® Trumenba®
Pneumococcal 13-valent conjugate vaccine	PCV13	Prevnar 13®
Pneumococcal 23-valent polysaccharide vaccine	PPSV23	Pneumovax 23®
Poliovirus vaccine (inactivated)	IPV	IPOL®
Rotavirus vaccine	RV1 RV5	Rotarix® RotaTeq®
Tetanus, diphtheria, and acellular pertussis vaccine	Tdap	Adacel® Boostrix®
Tetanus and diphtheria vaccine	Td	Tenivac® Tdvax™
Varicella vaccine	VAR	Varivax®
<b>Combination vaccines (use combination vaccines instead of separate injections when appropriate)</b>		
DTaP, hepatitis B, and inactivated poliovirus vaccine	DTaP-HepB-IPV	Pediarix®
DTaP, inactivated poliovirus, and <i>Haemophilus influenzae</i> type b vaccine	DTaP-IPV/Hib	Pentacel®
DTaP and inactivated poliovirus vaccine	DTaP-IPV	Kinrix® Quadracel®
DTaP, inactivated poliovirus, <i>Haemophilus influenzae</i> type b, and hepatitis B vaccine	DTaP-IPV-Hib-HepB	Vaxelis®
Measles, mumps, rubella, and varicella vaccine	MMRV	ProQuad®

\*Administer recommended vaccines if immunization history is incomplete or unknown. Do not restart or add doses to vaccine series for extended intervals between doses. When a vaccine is not administered at the recommended age, administer at a subsequent visit. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

## How to use the child/adolescent immunization schedule

- 1** Determine recommended vaccine by age (**Table 1**)
- 2** Determine recommended interval for catch-up vaccination (**Table 2**)
- 3** Assess need for additional recommended vaccines by medical condition and other indications (**Table 3**)
- 4** Review vaccine types, frequencies, intervals, and considerations for special situations (**Notes**)

Recommended by the Advisory Committee on Immunization Practices ([www.cdc.gov/vaccines/acip](http://www.cdc.gov/vaccines/acip)) and approved by the Centers for Disease Control and Prevention ([www.cdc.gov](http://www.cdc.gov)), American Academy of Pediatrics ([www.aap.org](http://www.aap.org)), American Academy of Family Physicians ([www.aafp.org](http://www.aafp.org)), American College of Obstetricians and Gynecologists ([www.acog.org](http://www.acog.org)), American College of Nurse-Midwives ([www.midwife.org](http://www.midwife.org)), American Academy of Physician Assistants ([www.aapa.org](http://www.aapa.org)), and National Association of Pediatric Nurse Practitioners ([www.napnap.org](http://www.napnap.org)).

## Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health department
- Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at [www.vaers.hhs.gov](http://www.vaers.hhs.gov) or 800-822-7967



Download the CDC Vaccine Schedules App for providers at [www.cdc.gov/vaccines/schedules/hcp/schedule-app.html](http://www.cdc.gov/vaccines/schedules/hcp/schedule-app.html).

## Helpful information

- Complete ACIP recommendations: [www.cdc.gov/vaccines/hcp/acip-recs/index.html](http://www.cdc.gov/vaccines/hcp/acip-recs/index.html)
- *General Best Practice Guidelines for Immunization*: [www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html](http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html)
- Outbreak information (including case identification and outbreak response), see Manual for the Surveillance of Vaccine-Preventable Diseases: [www.cdc.gov/vaccines/pubs/surv-manual](http://www.cdc.gov/vaccines/pubs/surv-manual)
- ACIP Shared Clinical Decision-Making Recommendations [www.cdc.gov/vaccines/acip/acip-scdm-faqs.html](http://www.cdc.gov/vaccines/acip/acip-scdm-faqs.html)



U.S. Department of  
Health and Human Services  
Centers for Disease  
Control and Prevention

**Table 1**

**Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2021**

These recommendations must be read with the notes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars. To determine minimum intervals between doses, see the catch-up schedule (Table 2). School entry and adolescent vaccine age groups are shaded in gray.

Vaccine	Birth	1 mo	2 mos	4 mos	6 mos	9 mos	12 mos	15 mos	18 mos	19-23 mos	2-3 yrs	4-6 yrs	7-10 yrs	11-12 yrs	13-15 yrs	16 yrs	17-18 yrs
Hepatitis B (HepB)	1 <sup>st</sup> dose	← 2 <sup>nd</sup> dose →		← 3 <sup>rd</sup> dose →													
Rotavirus (RV): RV1 (2-dose series), RV5 (3-dose series)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	See Notes												
Diphtheria, tetanus, acellular pertussis (DTaP <7 yrs)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	3 <sup>rd</sup> dose	← 4 <sup>th</sup> dose →			5 <sup>th</sup> dose								
<i>Haemophilus influenzae</i> type b (Hib)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	See Notes	← 3 <sup>rd</sup> or 4 <sup>th</sup> dose, See Notes →											
Pneumococcal conjugate (PCV13)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	3 <sup>rd</sup> dose	← 4 <sup>th</sup> dose →											
Inactivated poliovirus (IPV <18 yrs)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	← 3 <sup>rd</sup> dose →				4 <sup>th</sup> dose								
Influenza (IIV)	Annual vaccination 1 or 2 doses										Annual vaccination 1 dose only						
<b>OR</b>											Annual vaccination 1 or 2 doses						
Influenza (LAIV4)											Annual vaccination 1 dose only						
Measles, mumps, rubella (MMR)					See Notes	← 1 <sup>st</sup> dose →			2 <sup>nd</sup> dose								
Varicella (VAR)						← 1 <sup>st</sup> dose →			2 <sup>nd</sup> dose								
Hepatitis A (HepA)					See Notes	2-dose series, See Notes											
Tetanus, diphtheria, acellular pertussis (Tdap ≥7 yrs)														Tdap			
Human papillomavirus (HPV)														*	See Notes		
Meningococcal (MenACWY-D ≥9 mos, MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)			See Notes												1 <sup>st</sup> dose	2 <sup>nd</sup> dose	
Meningococcal B															See Notes		
Pneumococcal polysaccharide (PPSV23)														See Notes			

Range of recommended ages for all children
  Range of recommended ages for catch-up immunization
  Range of recommended ages for certain high-risk groups
  Recommended based on shared clinical decision-making or \*can be used in this age group
  No recommendation/ not applicable

**Table 2**

**Recommended Catch-up Immunization Schedule for Children and Adolescents Who Start Late or Who Are More than 1 month Behind, United States, 2021**

The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child's age. **Always use this table in conjunction with Table 1 and the notes that follow.**

Children age 4 months through 6 years					
Vaccine	Minimum Age for Dose 1	Minimum Interval Between Doses			
		Dose 1 to Dose 2	Dose 2 to Dose 3	Dose 3 to Dose 4	Dose 4 to Dose 5
Hepatitis B	Birth	<b>4 weeks</b>	<b>8 weeks and at least 16 weeks after first dose.</b> Minimum age for the final dose is 24 weeks.		
Rotavirus	6 weeks Maximum age for first dose is 14 weeks, 6 days.	<b>4 weeks</b>	<b>4 weeks</b> Maximum age for final dose is 8 months, 0 days.		
Diphtheria, tetanus, and acellular pertussis	6 weeks	<b>4 weeks</b>	<b>4 weeks</b>	<b>6 months</b>	<b>6 months</b>
<i>Haemophilus influenzae</i> type b	6 weeks	<b>No further doses needed</b> if first dose was administered at age 15 months or older. <b>4 weeks</b> if first dose was administered before the 1 <sup>st</sup> birthday. <b>8 weeks (as final dose)</b> if first dose was administered at age 12 through 14 months.	<b>No further doses needed</b> if previous dose was administered at age 15 months or older. <b>4 weeks</b> if current age is younger than 12 months <b>and</b> first dose was administered at younger than age 7 months <b>and</b> at least 1 previous dose was PRP-T (ActHib, Pentacel, Hiberix) or unknown. <b>8 weeks and age 12 through 59 months (as final dose)</b> if current age is younger than 12 months <b>and</b> first dose was administered at age 7 through 11 months; OR If current age is 12 through 59 months <b>and</b> first dose was administered before the 1 <sup>st</sup> birthday <b>and</b> second dose was administered at younger than 15 months; OR if both doses were PRP-OMP (Pedvax-Hib, Comvax) <b>and</b> were administered before the 1 <sup>st</sup> birthday.	<b>8 weeks (as final dose)</b> This dose only necessary for children age 12 through 59 months who received 3 doses before the 1 <sup>st</sup> birthday.	
Pneumococcal conjugate	6 weeks	<b>No further doses needed</b> for healthy children if first dose was administered at age 24 months or older. <b>4 weeks</b> if first dose was administered before the 1 <sup>st</sup> birthday. <b>8 weeks (as final dose for healthy children)</b> if first dose was administered at the 1 <sup>st</sup> birthday or after.	<b>No further doses needed</b> for healthy children if previous dose was administered at age 24 months or older. <b>4 weeks</b> if current age is younger than 12 months and previous dose was administered at <7 months old. <b>8 weeks (as final dose for healthy children)</b> if previous dose was administered between 7–11 months (wait until at least 12 months old); OR if current age is 12 months or older and at least 1 dose was administered before age 12 months.	<b>8 weeks (as final dose)</b> This dose only necessary for children age 12 through 59 months who received 3 doses before age 12 months or for children at high risk who received 3 doses at any age.	
Inactivated poliovirus	6 weeks	<b>4 weeks</b>	<b>4 weeks</b> if current age is <4 years. <b>6 months (as final dose)</b> if current age is 4 years or older.	<b>6 months</b> (minimum age 4 years for final dose).	
Measles, mumps, rubella	12 months	<b>4 weeks</b>			
Varicella	12 months	<b>3 months</b>			
Hepatitis A	12 months	<b>6 months</b>			
Meningococcal ACWY	2 months MenACWY-CRM 9 months MenACWY-D 2 years MenACWY-TT	<b>8 weeks</b>	See Notes	See Notes	
Children and adolescents age 7 through 18 years					
Meningococcal ACWY	Not applicable (N/A)	<b>8 weeks</b>			
Tetanus, diphtheria; tetanus, diphtheria, and acellular pertussis	7 years	<b>4 weeks</b>	<b>4 weeks</b> if first dose of DTaP/DT was administered before the 1 <sup>st</sup> birthday. <b>6 months (as final dose)</b> if first dose of DTaP/DT or Tdap/Td was administered at or after the 1 <sup>st</sup> birthday.	<b>6 months</b> if first dose of DTaP/DT was administered before the 1 <sup>st</sup> birthday.	
Human papillomavirus	9 years	<b>Routine dosing intervals are recommended.</b>			
Hepatitis A	N/A	<b>6 months</b>			
Hepatitis B	N/A	<b>4 weeks</b>	<b>8 weeks and at least 16 weeks after first dose.</b>		
Inactivated poliovirus	N/A	<b>4 weeks</b>	<b>6 months</b> A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose.	A fourth dose of IPV is indicated if all previous doses were administered at <4 years or if the third dose was administered <6 months after the second dose.	
Measles, mumps, rubella	N/A	<b>4 weeks</b>			
Varicella	N/A	<b>3 months</b> if younger than age 13 years. <b>4 weeks</b> if age 13 years or older.			



**Table 1**

**Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2021**

These recommendations must be read with the notes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars. To determine minimum intervals between doses, see the catch-up schedule (Table 2). School entry and adolescent vaccine age groups are shaded in gray.

Vaccine	Birth	1 mo	2 mos	4 mos	6 mos	9 mos	12 mos	15 mos	18 mos	19-23 mos	2-3 yrs	4-6 yrs	7-10 yrs	11-12 yrs	13-15 yrs	16 yrs	17-18 yrs		
Hepatitis B (HepB)	1 <sup>st</sup> dose	← 2 <sup>nd</sup> dose →		← 3 <sup>rd</sup> dose →															
Rotavirus (RV): RV1 (2-dose series), RV5 (3-dose series)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	See Notes														
Diphtheria, tetanus, acellular pertussis (DTaP <7 yrs)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	3 <sup>rd</sup> dose				← 4 <sup>th</sup> dose →			5 <sup>th</sup> dose							
<i>Haemophilus influenzae</i> type b (Hib)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	See Notes				← 3 <sup>rd</sup> or 4 <sup>th</sup> dose, See Notes →										
Pneumococcal conjugate (PCV13)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	3 <sup>rd</sup> dose				← 4 <sup>th</sup> dose →										
Inactivated poliovirus (IPV <18 yrs)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	← 3 <sup>rd</sup> dose →						4 <sup>th</sup> dose								
Influenza (IIV)						Annual vaccination 1 or 2 doses							Annual vaccination 1 dose only						
<b>OR</b>											Annual vaccination 1 or 2 doses		<b>OR</b> Annual vaccination 1 dose only						
Influenza (LAIV4)											Annual vaccination 1 or 2 doses		Annual vaccination 1 dose only						
Measles, mumps, rubella (MMR)					See Notes	← 1 <sup>st</sup> dose →					2 <sup>nd</sup> dose								
Varicella (VAR)						← 1 <sup>st</sup> dose →					2 <sup>nd</sup> dose								
Hepatitis A (HepA)					See Notes	2-dose series, See Notes													
Tetanus, diphtheria, acellular pertussis (Tdap ≥7 yrs)															Tdap				
Human papillomavirus (HPV)															*	See Notes			
Meningococcal (MenACWY-D ≥9 mos, MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)			See Notes													1 <sup>st</sup> dose		2 <sup>nd</sup> dose	
Meningococcal B																See Notes			
Pneumococcal polysaccharide (PPSV23)															See Notes				

  Range of recommended ages for all children
   Range of recommended ages for catch-up immunization
   Range of recommended ages for certain high-risk groups
   Recommended based on shared clinical decision-making or \*can be used in this age group
   No recommendation/ not applicable

# Adolescent Immunization Issues

# Adolescent Immunization Issues

- Timing and spacing
- Vaccine administration – needle length
- Syncope

# Timing and Spacing of Vaccine Doses

- General Best Practices: two different vaccines may be given simultaneously (same clinic day)
  - Non-simultaneous: if vaccines are both live, must be spaced by 28 days
- COVID-19 vaccine and other vaccines: may be administered simultaneously or at any interval between them (COVID-19 vaccines are non-live)
- COVID-19 vaccine and vaccines that are reactogenic (tetanus-toxoid containing vaccine, adjuvanted vaccines) should be administered in different limbs

# Timing and Spacing of Vaccine Doses: Adjuvanted Routine Vaccines

- Hepatitis B, DTaP, IIV (Fluad), Tdap, HPV, Zoster (RZV), Pentacel, Pediarix, Quadracel, Kinrix, Twinrix.
- Vaccines administered to adolescents: Tdap, HPV, Twinrix (18 years and older), HepB (Heplisav, 18 years and older)

# Vaccine Administration: Needle Length



TABLE 6-2. Needle length and injection site of IM injections for children aged ≤18 years (by age) and adults aged ≥19 years (by sex and weight)

Age group	Needle length	Injection site
<b>Children (birth-18 years)</b>		
Neonates <sup>(a)</sup>	5/8 inch (16 mm) <sup>(b)</sup>	Anterolateral thigh
Infants, 1-12 months	1 inch (25 mm)	Anterolateral thigh
Toddlers, 1-2 years	1-1.25 inch (25-32 mm)	Anterolateral thigh <sup>(c)</sup>
	5/8 <sup>(b)</sup> -1 inch (16-25 mm)	Deltoid muscle of arm
Children, 3-10 years	5/8 <sup>(b)</sup> -1 inch (16-25 mm)	Deltoid muscle of arm <sup>(d)</sup>
	1-1.25 inches (25-32 mm)	Anterolateral thigh
Children, 11-18 years	5/8 <sup>(b)</sup> -1 inch (16-25 mm)	Deltoid muscle of arm <sup>(d)</sup>
	1-1.5 inches (25-38 mm)	Anterolateral thigh
<b>Adults (≥19 years)</b>		
Men and women, <60 kg (130 lbs)	1 inch (25 mm) <sup>(e)</sup>	Deltoid muscle of arm
Men and women, 60-70 kg (130-152 lbs)	1 inch (25 mm)	
Men, 70-118 kg (152-260 lbs)	1-1.5 inches (25-38 mm)	
Women, 70-90 kg (152-200 lbs)		
Men, >118 kg (260 lbs)	1.5 inches (38 mm)	
Women, >90 kg (200 lbs)		
Abbreviation: IM = intramuscular. Source: (14).		

<sup>(a)</sup> First 28 days of life.  
<sup>(b)</sup> If skin is stretched tightly and subcutaneous tissues are not bunched.  
<sup>(c)</sup> Preferred site.  
<sup>(d)</sup> Some experts recommend a 5/8-inch needle for men and women who weigh <60 kg; if used, skin must be stretched tightly (do not bunch subcutaneous tissue).

# Vaccine Needle Length: Children 11 Years Through 18 Years

- Deltoid Muscle (preferred site)
  - 5/8 inch through 1 inch
  - 5/8 inch only if the skin is stretched tight and the subcutaneous tissues are not bunched
  
- Anterolateral thigh
  - 1 through 1.5 inches



# Vaccine Needle Length: COVID-19 Vaccine Issues

## ■ RECONSTITUTION

- Pfizer COVID-19 vaccine
  - Vaccine must be reconstituted and the recommended syringe size varies for reconstitution and injection into the patient


## ■ MULTIDOSE VIALS

- mRNA COVID-19 vaccine (Pfizer and Moderna)
  - Needle length should be based on technique, but for persons 19 years old and older (some adolescents) the needle length is based on weight.
  - Need to use a 1.5 inch vaccine to administer into the deltoid for high-weight patient, but USP recommends using a 1 inch needle to draw up vaccines (and switch needles)
  - 1.5 inch needles may not fit both low-dead-volume syringes AND traditional volume syringes
    - › Auxiliary kits contain 80% (per vial) low-dead-volume syringes
    - › CDC recommends using 50% low-dead-volume syringe and traditional volume syringe when pre-filling from a vial (to produce maximum dose sparing)




# Special Adolescent Concern

History of immediate allergic reaction (any severity) to a vaccine or injectable therapy  
Contraindication to a different type of COVID-19 vaccine  
History of anaphylaxis (due to any cause)



30 minutes

All other persons



15 minutes



**WE  
CAN  
DO  
THIS**

# Pink Book Webinar Updates

# Pink Book Updates

- First vaccine-specific Pink Book presentation of 2020 webinar series: August 5, 2020
- There will not be a 2021 Pink Book Webinar series
- Updates to Vaccine-Specific Recommendations have been made to:
  - DTaP
  - Tdap
  - Vaccine administration
  - LAIV
  - Zoster vaccine
  - MenACWY
  - MenB
  - HPV

# DTaP Updates

- Minimum intervals between 3<sup>rd</sup> and 4<sup>th</sup> dose
  - 6 months prospectively and IIS forecasting
  - 4 months retrospectively and IIS evaluation
  
- Minimum interval between the penultimate and ultimate dose of DTaP
  - 6 months (both prospective and retrospective)

# Tdap Vaccine

- Tdap vaccine recommended for current pregnancy
- Tdap vaccine recommended for adolescence
- 2<sup>nd</sup> dose of Tdap recommended for 11-12 year olds, even if a first dose of Tdap was administered as catch-up between 7 years through 9 years
- For other recommended tetanus-toxoid containing vaccines, EITHER Tdap or Td may be used

# Vaccine Administration

- Doses of vaccine from two separate vials should NOT be pooled to create one or more vaccine doses
- Can lead to product contamination